Text Size

Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms

This study is currently recruiting participants.
Verified November 2012 by Rigshospitalet, Denmark
Sponsor:
Collaborators:
Danish Breast Cancer Cooperative Group
Danish Cancer Society
Information provided by (Responsible Party):
Kenneth Geving Andersen, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01523132
First received: January 27, 2012
Last updated: November 22, 2012
Last verified: November 2012
History of Changes
  Purpose

The study is a prospective cohort study following breast cancer patients from before surgery to one year after. The aims of the study are to determine risk factors that predispose to the development of persistent pain.


Condition
Breast Cancer
Persistent Pain
Lymphedema
Neuropathic Pain
Neuropathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Risk factors predisposing for persistent pain after breast cancer treatment [ Time Frame: 12 months postoperative ] [ Designated as safety issue: Yes ]
    Pre-, intra- and postoperative risk factors predisposing for persistent pain


Secondary Outcome Measures:
  • Prevalence of persistent pain after breast cancer treatment [ Time Frame: 12 months postoperative ] [ Designated as safety issue: No ]
  • Prevalence of sensory disturbances after breast cancer treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Correlation of persistent pain after breast cancer treatment and damage of the intercostobrachial nerve [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Quantitative sensory testing: profile and correlation to persistent pain, sensory disturbances, signs of neuropathic pain, and treatment related factors [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Genetic markers and the development of persistent pain after breast cancer treatment [ Time Frame: 12 months postoperative ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

blood


Estimated Enrollment: 400
Study Start Date: November 2011
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Breast cancer patients
Female breast cancer patients without metastasis and locally advanced disease

Detailed Description:

The aim of the study is 1) to determine pre-, intra and post surgical risk factors for persistent pain after breast cancer treatment 2) to examine the prevalence of persistent pain 6 and 12 months after surgery 3) provide a quantitative sensory testing (QST) profile of the patient population, measured pre surgery, 1 week and 12 months after surgery.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Breast cancer patients treated in a university hospital

Criteria

Inclusion Criteria:

  • Diagnosed with breast cancer
  • 18 years or older

Exclusion Criteria:

  • unable to give written consent
  • unable to understand Danish
  • Previous cosmetic surgery in the breast
  • Previous surgery in ipsilateral breast
  • Bilateral cancer
  • Concomitant corrective surgery on contralateral side
  • Pregnant
  • Other disease or injury in the nervous system
  • Psychiatric disease
  • Alcohol or drug abuse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01523132

Contacts
Contact: Kenneth Geving Andersen, MD +35454496 kenneth.geving.andersen@rh.regionh.dk

Locations
Denmark
Rigshospitalet, Copenhagen University Hospital Recruiting
Copenhagen, Denmark, DK-2100
Contact: Kenneth Geving Andersen, MD            
Sponsors and Collaborators
Rigshospitalet, Denmark
Danish Breast Cancer Cooperative Group
Danish Cancer Society
Investigators
Principal Investigator: Kenneth Geving Andersen, MD Rigshospitalet, Denmark
Study Chair: Henrik Kehlet, MD, PhD Rigshospitalet, Denmark
  More Information

Publications:

Responsible Party: Kenneth Geving Andersen, Physician, research fellow, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT01523132     History of Changes
Other Study ID Numbers: H-D-2007-0098
Study First Received: January 27, 2012
Last Updated: November 22, 2012
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Additional relevant MeSH terms:
Breast Neoplasms
Lymphedema
Neuralgia
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
 Lymphatic Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on May 21, 2013